Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia

NCT00249912 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00249912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00249912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
April 30, 2007
Enrollment
415 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia